Key Points
- Susan Bobulsky sold 3,000 Adaptive Biotechnologies shares at $25 each, for total proceeds of $75,000. The Rule 10b5-1 transaction reduced her stake by 0.75%, leaving her with 396,989 shares.
- Adaptive Biotechnologies reported quarterly revenue of $71.55 million, up 21.5% year over year and above estimates, but its loss of $0.25 per share exceeded analysts’ expected loss of $0.13.
- Analyst sentiment remains broadly positive, with a “Moderate Buy” consensus and an average price target of $24.42, while the stock recently traded near its 52-week high of $26.16.
Adaptive Biotechnologies Corporation (NASDAQ:ADPT - Get Free Report) insider Susan Bobulsky sold 3,000 shares of the firm's stock in a transaction on Monday, August 10th. The stock was sold at an average price of $25.00, for a total value of $75,000.00. Following the completion of the transaction, the insider owned 396,989 shares of the company's stock, valued at $9,924,725. This trade represents a 0.75% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Susan Bobulsky also recently made the following trade(s):
- On Thursday, July 30th, Susan Bobulsky sold 1,299 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $24.00, for a total value of $31,176.00.
- On Wednesday, July 1st, Susan Bobulsky sold 487 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $22.00, for a total value of $10,714.00.
- On Thursday, June 11th, Susan Bobulsky sold 5,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $19.00, for a total value of $95,000.00.
- On Thursday, June 4th, Susan Bobulsky sold 11,000 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $18.00, for a total value of $198,000.00.
Adaptive Biotechnologies Price Performance
Shares of NASDAQ ADPT opened at $25.25 on Thursday. Adaptive Biotechnologies Corporation has a 52 week low of $11.92 and a 52 week high of $26.16. The business's 50 day moving average price is $21.00 and its 200 day moving average price is $17.02. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The firm has a market cap of $4.03 billion, a P/E ratio of -61.59 and a beta of 2.08.
Adaptive Biotechnologies (NASDAQ:ADPT - Get Free Report) last posted its quarterly earnings results on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.12). The business had revenue of $71.55 million for the quarter, compared to analysts' expectations of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business's quarterly revenue was up 21.5% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.17) earnings per share. On average, sell-side analysts expect that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have weighed in on the company. Morgan Stanley increased their price target on Adaptive Biotechnologies from $20.00 to $22.00 and gave the stock an "equal weight" rating in a research report on Thursday, July 30th. BTIG Research boosted their price objective on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, July 30th. JPMorgan Chase & Co. lowered their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Adaptive Biotechnologies in a report on Friday, July 17th. Finally, Guggenheim boosted their price target on Adaptive Biotechnologies from $22.00 to $25.00 and gave the company a "buy" rating in a report on Thursday, July 30th. Five equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $24.42.
Get Our Latest Research Report on Adaptive Biotechnologies
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in ADPT. Caitong International Asset Management Co. Ltd purchased a new position in Adaptive Biotechnologies in the 4th quarter worth approximately $28,000. Allworth Financial LP purchased a new position in Adaptive Biotechnologies in the second quarter worth approximately $35,000. EverSource Wealth Advisors LLC increased its stake in Adaptive Biotechnologies by 197.1% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company's stock worth $38,000 after acquiring an additional 1,565 shares during the last quarter. KBC Group NV purchased a new stake in Adaptive Biotechnologies in the first quarter valued at $45,000. Finally, Assetmark Inc. grew its holdings in shares of Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company's stock worth $49,000 after purchasing an additional 2,708 shares during the period. 99.17% of the stock is owned by institutional investors and hedge funds.
Adaptive Biotechnologies Company Profile
(
Get Free Report)
Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.
The company's flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
